Total Liabilities for Vertex Pharmaceuticals (VRTX)
According to Vertex Pharmaceuticals's latest reported financial statements, the company's latest reported total liabilities is $7.48B USD. Total liabilities sum everything the company owes at the end of each reporting period — accounts payable, accrued expenses, debt, lease obligations, and other claims — as filed on the balance sheet. Compare with total assets and net assets for solvency context.
Headline figure above is from the reporting period ending (reported ). Chart and table below cover the full reported history back to .
Currently viewingTotal LiabilitiesSwitch metric
Latest period
$7.48B
YoY change
+22.1%
5Y CAGR
+19.5%
Peak year (2025)
$7.48B
Latest annual
$7.48B
Total Liabilities history chart for Vertex Pharmaceuticals (VRTX) from 1990 to 2025
Total Liabilities history table for Vertex Pharmaceuticals (VRTX) from 1990 to 2025
| Fiscal year | Period ended | Reported | Total Liabilities | YoY |
|---|---|---|---|---|
| 2025 | $7.48B | +22.1% | ||
| 2024 | $6.12B | +18.9% | ||
| 2023 | $5.15B | +21.5% | ||
| 2022 | $4.24B | +27.2% | ||
| 2021 | $3.33B | +8.7% | ||
| 2020 | $3.06B | +37.2% | ||
| 2019 | $2.23B | +23.3% | ||
| 2018 | $1.81B | +20.4% | ||
| 2017 | $1.50B | -3.5% | ||
| 2016 | $1.56B | +10.9% | ||
| 2015 | $1.40B | +13.4% | ||
| 2014 | $1.24B | +28.7% | ||
| 2013 | $962.64M | -38.4% | ||
| 2012 | $1.56B | +22.5% | ||
| 2011 | $1.28B | +4.4% | ||
| 2010 | $1.22B | +42.2% | ||
| 2009 | $859.14M | +15.8% | ||
| 2008 | $741.61M | +124.6% | ||
| 2007 | $330.18M | -20.6% | ||
| 2006 | $415.64M | +34.2% | ||
| 2005 | $309.82M | -39.3% | ||
| 2004 | $510.01M | -4.1% | ||
| 2003 | $531.57M | +21.6% | ||
| 2002 | $437.14M | -2.8% | ||
| 2001 | $449.78M | +5.3% | ||
| 2000 | $427.13M | +1740.2% | ||
| 1999 | $23.21M | +15.5% | ||
| 1998 | $20.10M | +2.6% | ||
| 1997 | $19.60M | +54.3% | ||
| 1996 | $12.70M | -7.3% | ||
| 1995 | $13.70M | +28.0% | ||
| 1994 | $10.70M | -7.0% | ||
| 1993 | $11.50M | +62.0% | ||
| 1992 | $7.10M | +44.9% | ||
| 1991 | $4.90M | +22.5% | ||
| 1990 | $4.00M | — |
Total Liabilities values are taken from Vertex Pharmaceuticals's reported balance sheets (10-Q quarterly and 10-K annual filings with the U.S. Securities and Exchange Commission). Each row shows the period end date and the date the filing was reported; YoY compares each figure to the same period one year earlier. Amounts are in USD as filed.
Analysis
Vertex Pharmaceuticals (VRTX) most recent annual total liabilities stands at $7.48B (2025) – grew 22.1% year-over-year.
Through 2020–2025 (5 years), Vertex Pharmaceuticals total liabilities delivered a +19.5% annualised rate; with the latest reading among the more recent periods of the dataset.
Across the available history, total liabilities reached its high of $7.48B in 2025 and its low of $4.00M in 1990.
Vertex Pharmaceuticals (VRTX) sits 9th of 8 Healthcare peers we track on this metric, against a peer median of $101.80B.
Vertex Pharmaceuticals Total Liabilities by Year
Vertex Pharmaceuticals Total Liabilities 2025: $7.48B
Vertex Pharmaceuticals total liabilities in 2025 was $7.48B, grew 22.1% from 2024. This figure represents the highest annual value in the available history.
Vertex Pharmaceuticals Total Liabilities 2024: $6.12B
Vertex Pharmaceuticals total liabilities in 2024 was $6.12B, grew 18.9% from 2023.
Vertex Pharmaceuticals Total Liabilities 2023: $5.15B
Vertex Pharmaceuticals total liabilities in 2023 was $5.15B, grew 21.5% from 2022.
Vertex Pharmaceuticals Total Liabilities 2022: $4.24B
Vertex Pharmaceuticals total liabilities in 2022 was $4.24B, grew 27.2% from 2021.
Vertex Pharmaceuticals Total Liabilities 2021: $3.33B
Vertex Pharmaceuticals total liabilities in 2021 was $3.33B.
See more financial history for Vertex Pharmaceuticals (VRTX).
Sector peers — Total Liabilities
Companies in the same sector as Vertex Pharmaceuticals, ranked by their latest total liabilities.
| Company | Total Liabilities | Sector |
|---|---|---|
| Novo Nordisk A/S (NVO) | $348.86B | Healthcare |
| UnitedHealth Group Incorporated (UNH) | $207.88B | Healthcare |
| AbbVie Inc. (ABBV) | $137.19B | Healthcare |
| Johnson & Johnson (JNJ) | $117.67B | Healthcare |
| Eli Lilly and Company (LLY) | $85.94B | Healthcare |
| Merck & Co., Inc. (MRK) | $84.20B | Healthcare |
| Amgen Inc. (AMGN) | $81.93B | Healthcare |
| AstraZeneca PLC (AZN) | $65.36B | Healthcare |
Frequently asked questions
What is Vertex Pharmaceuticals's total liabilities?
- Latest reported total liabilities for Vertex Pharmaceuticals (VRTX) is $7.48B (period ending December 31, 2025).
How has Vertex Pharmaceuticals total liabilities changed year-over-year?
- Vertex Pharmaceuticals (VRTX) total liabilities changed +22.1% year-over-year on the latest annual filing.
What is the long-term growth rate of Vertex Pharmaceuticals total liabilities?
- Vertex Pharmaceuticals (VRTX) total liabilities compound annual growth rate is +19.5% over the most recent 5 years available.
When did Vertex Pharmaceuticals total liabilities hit its highest annual value?
- Vertex Pharmaceuticals total liabilities reached its highest annual value of $7.48B in 2025.
What was Vertex Pharmaceuticals total liabilities in 2024?
- Vertex Pharmaceuticals (VRTX) total liabilities in 2024 was $6.12B.
What was Vertex Pharmaceuticals total liabilities in 2025?
- Vertex Pharmaceuticals (VRTX) total liabilities in 2025 was $7.48B.
Metrics overview
Pick a metric for charts, filings, and peers — each row shows the latest TTM or annual value with year-over-year change.
Explore more
VRTX Overview
Company profile, financial tools, and key metrics
VRTX Revenue Counter
Earns $381.74 every second. See per minute, hour, and day.
VRTX Earnings Counter
Earns $125.36 per second net profit. See per minute, hour, and day.
VRTX Economic Scale
Exceeds Somalia, Fed. Rep.'s GDP. Compare with world economies.
VRTX What If Invested
What if you had invested $1,000? See historical returns from any date.
VRTX How It Makes Money
Discover visual breakdown of $12.04B in revenue — where it comes from and where it goes.
VRTX Stock Seasonality
Best and worst months to invest. Historical monthly returns heatmap.
VRTX Price Target Scenarios
Model bear, base, and bull cases with EPS growth and exit P/E — pre-filled from analysts and history.
VRTX Daily Price Character
Explosive · 48.3% historical win rate (green days). Streaks & record days.
VRTX Buybacks
1.75% TTM buyback yield. Shareholder yield & SBC comparison.
VRTX Stock Split History
1 split on record. Dates, ratios, and cumulative multiple.